Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial

BACKGROUND: Type-1 diabetes (T1D) occurs following autoimmune-induced pancreatic beta cells death. Among several treatment modalities, mesenchymal stem cells (MSCs) transplantation is promising for autoimmune disorders due to immunomodulation, regeneration, and migration to damaged tissue upon syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Izadi, Mahmoud, Sadr Hashemi Nejad, Anavasadat, Moazenchi, Maedeh, Masoumi, Safdar, Rabbani, Ali, Kompani, Farzad, Hedayati Asl, Amir Abbas, Abbasi Kakroodi, Fatemeh, Jaroughi, Neda, Mohseni Meybodi, Mohammad Ali, Setoodeh, Aria, Abbasi, Farzaneh, Hosseini, Seyedeh Esmat, Moeini Nia, Fatemeh, Salman Yazdi, Reza, Navabi, Roghayeh, Hajizadeh-Saffar, Ensiyeh, Baharvand, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208234/
https://www.ncbi.nlm.nih.gov/pubmed/35725652
http://dx.doi.org/10.1186/s13287-022-02941-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208234/
https://www.ncbi.nlm.nih.gov/pubmed/35725652
http://dx.doi.org/10.1186/s13287-022-02941-w

Ejemplares similares